The Association of Plasma Cystatin C Proteoforms with Diabetic Chronic Kidney Disease

Overview

Journal Proteome Sci

Publisher Biomed Central

Date 2016 Mar 29

PMID 27019641

Citations 14

Authors

Hussein N Yassine

Olgica Trenchevska

Zhiwei Dong

Yara Bashawri

Juraj Koska

Peter D Reaven

Randall W Nelson

Dobrin Nedelkov

Affiliations

Soon will be listed here.

Abstract

Background: Cystatin C (CysC) is an endogenous cysteine protease inhibitor that can be used to assess the progression of kidney function. Recent studies demonstrate that CysC is a more specific indicator of glomerular filtration rate (GFR) than creatinine. CysC in plasma exists in multiple proteoforms. The goal of this study was to clarify the association of native CysC, CysC missing N-terminal Serine (CysC des-S), and CysC without three N-terminal residues (CysC des-SSP) with diabetic chronic kidney disease (CKD).

Results: Using mass spectrometric immunoassay, the plasma concentrations of native CysC and the two CysC truncation proteoforms were examined in 111 individuals from three groups: 33 non-diabetic controls, 34 participants with type 2 diabetes (DM) and without CKD and 44 participants with diabetic CKD. Native CysC concentrations were 1.4 fold greater in CKD compared to DM group (p = 0.02) and 1.5 fold greater in CKD compared to the control group (p = 0.001). CysC des-S concentrations were 1.55 fold greater in CKD compared to the DM group (p = 0.002) and 1.9 fold greater in CKD compared to the control group (p = 0.0002). CysC des-SSP concentrations were 1.8 fold greater in CKD compared to the DM group (p = 0.008) and 1.52 fold greater in CKD compared to the control group (p = 0.002). In addition, the concentrations of CysC proteoforms were greater in the setting of albuminuria. The truncated CysC proteoform concentrations were associated with estimated GFR independent of native CysC concentrations.

Conclusion: Our findings demonstrate a greater amount of CysC proteoforms in diabetic CKD. We therefore suggest assessing the role of cystatin C proteoforms in the progression of CKD.

Citing Articles

Serum Cystatin C as a Risk Factor for Supratherapeutic Digoxin Concentration in Elderly Patients with Heart Failure and Chronic Kidney Disease.

Lu J, Liu T Am J Cardiovasc Drugs. 2024; 24(2):303-311.

PMID: 38300453 DOI: 10.1007/s40256-024-00629-5.

Apo CIII Proteoforms, Plasma Lipids, and Cardiovascular Risk in MESA.

Sinari S, Koska J, Hu Y, Furtado J, Jensen M, Budoff M Arterioscler Thromb Vasc Biol. 2023; 43(8):1560-1571.

PMID: 37317850 PMC: 10516344. DOI: 10.1161/ATVBAHA.123.319035.

Association of Cystatin C Proteoforms with Estimated Glomerular Filtration Rate.

Trenchevska O, Koska J, Sinari S, Yassine H, Reaven P, Billheimer D Clin Mass Spectrom. 2023; 1:27-31.

PMID: 36778895 PMC: 9913891. DOI: 10.1016/j.clinms.2016.11.001.

Cystatin C proteoforms in chronic kidney disease.

Dahl H, Meyer K, Sandnes K, Welland N, Arnesen I, Marti H PLoS One. 2023; 18(2):e0269436.

PMID: 36724153 PMC: 9891521. DOI: 10.1371/journal.pone.0269436.

A nomogram for predicting the 4-year risk of chronic kidney disease among Chinese elderly adults.

Zhang L, Tang L, Chen S, Chen C, Peng B Int Urol Nephrol. 2023; 55(6):1609-1617.

PMID: 36720744 DOI: 10.1007/s11255-023-03470-y.

References

Ekiel I, Abrahamson M, Fulton D, Lindahl P, Storer A, Levadoux W . NMR structural studies of human cystatin C dimers and monomers. J Mol Biol. 1997; 271(2):266-77. DOI: 10.1006/jmbi.1997.1150. View

Abrahamson M, Mason R, Hansson H, Buttle D, Grubb A, Ohlsson K . Human cystatin C. role of the N-terminal segment in the inhibition of human cysteine proteinases and in its inactivation by leucocyte elastase. Biochem J. 1991; 273 ( Pt 3):621-6. PMC: 1149809. DOI: 10.1042/bj2730621. View

Shlipak M, Matsushita K, Arnlov J, Inker L, Katz R, Polkinghorne K . Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med. 2013; 369(10):932-43. PMC: 3993094. DOI: 10.1056/NEJMoa1214234. View

BJORK I, Pol E, Abrahamson M, Rowan A, Mort J . Differential changes in the association and dissociation rate constants for binding of cystatins to target proteinases occurring on N-terminal truncation of the inhibitors indicate that the interaction mechanism varies with different enzymes. Biochem J. 1994; 299 ( Pt 1):219-25. PMC: 1138045. DOI: 10.1042/bj2990219. View

Froissart M, Rossert J, Jacquot C, Paillard M, Houillier P . Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol. 2005; 16(3):763-73. DOI: 10.1681/ASN.2004070549. View

Song S, Meyer M, Turk T, Wilde B, Feldkamp T, Assert R . Serum cystatin C in mouse models: a reliable and precise marker for renal function and superior to serum creatinine. Nephrol Dial Transplant. 2008; 24(4):1157-61. DOI: 10.1093/ndt/gfn626. View

Stevens L, Coresh J, Greene T, Levey A . Assessing kidney function--measured and estimated glomerular filtration rate. N Engl J Med. 2006; 354(23):2473-83. DOI: 10.1056/NEJMra054415. View

Mussap M, Plebani M . Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci. 2004; 41(5-6):467-550. DOI: 10.1080/10408360490504934. View

Yassine H, Trenchevska O, He H, Borges C, Nedelkov D, Mack W . Serum amyloid a truncations in type 2 diabetes mellitus. PLoS One. 2015; 10(1):e0115320. PMC: 4301920. DOI: 10.1371/journal.pone.0115320. View

10.

Tenstad O, Roald A, Grubb A, Aukland K . Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest. 1996; 56(5):409-14. DOI: 10.3109/00365519609088795. View

11.

Yassine H, Borges C, Schaab M, Billheimer D, Stump C, Reaven P . Mass spectrometric immunoassay and MRM as targeted MS-based quantitative approaches in biomarker development: potential applications to cardiovascular disease and diabetes. Proteomics Clin Appl. 2013; 7(7-8):528-40. PMC: 4029342. DOI: 10.1002/prca.201200028. View

12.

Popovic T, Cimerman N, Dolenc I, Ritonja A, Brzin J . Cathepsin L is capable of truncating cystatin C of 11 N-terminal amino acids. FEBS Lett. 1999; 455(1-2):92-6. DOI: 10.1016/s0014-5793(99)00824-8. View

13.

Stevens L, Coresh J, Schmid C, Feldman H, Froissart M, Kusek J . Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis. 2008; 51(3):395-406. PMC: 2390827. DOI: 10.1053/j.ajkd.2007.11.018. View

14.

Abrahamson M, Olafsson I, Palsdottir A, Ulvsback M, Lundwall A, Jensson O . Structure and expression of the human cystatin C gene. Biochem J. 1990; 268(2):287-94. PMC: 1131430. DOI: 10.1042/bj2680287. View

15.

Andreev E, Koopman M, Arisz L . A rise in plasma creatinine that is not a sign of renal failure: which drugs can be responsible?. J Intern Med. 1999; 246(3):247-52. DOI: 10.1046/j.1365-2796.1999.00515.x. View

16.

Trenchevska O, Phillips D, Nelson R, Nedelkov D . Delineation of concentration ranges and longitudinal changes of human plasma protein variants. PLoS One. 2014; 9(6):e100713. PMC: 4067327. DOI: 10.1371/journal.pone.0100713. View

17.

Levey A, de Jong P, Coresh J, El Nahas M, Astor B, Matsushita K . The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2010; 80(1):17-28. DOI: 10.1038/ki.2010.483. View

18.

Jarvinen M, Rinne A, Hopsu-Havu V . Human cystatins in normal and diseased tissues--a review. Acta Histochem. 1987; 82(1):5-18. DOI: 10.1016/S0065-1281(87)80043-0. View

19.

Kopple J . National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis. 2001; 37(1 Suppl 2):S66-70. DOI: 10.1053/ajkd.2001.20748. View

20.

Trenchevska O, Nedelkov D . Targeted quantitative mass spectrometric immunoassay for human protein variants. Proteome Sci. 2011; 9(1):19. PMC: 3080279. DOI: 10.1186/1477-5956-9-19. View